Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
For a patient with NSCLC and a targetable mutation that transforms into SCLC, would you immunotherapy to chemotherapy?
For example, would you avoid immunotherapy in a patient with EGFR+ NSCLC due to its EGFR mutated?